Acute heart failure with preserved ejection fraction: Unique patient characteristics and targets for therapy

Current Heart Failure Reports

Volumn 10, Issue 3, 2013, Pages 190-197

  Bishu, Kalkidan ^a   Redfield, Margaret M ^a  

^a MAYO CLINIC   (United States)

Author keywords

Heart failure with preserved ejection fraction

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; DOPAMINE; LOOP DIURETIC AGENT; NESIRITIDE; NITROPRUSSIDE SODIUM; SERELAXIN; THIAZIDE DIURETIC AGENT;

ALDOSTERONE BLOOD LEVEL; ARTICLE; CENTRAL SLEEP APNEA SYNDROME; CLINICAL FEATURE; COMORBIDITY; CORONARY ARTERY DISEASE; DEMOGRAPHY; DIASTOLIC DYSFUNCTION; DIURETIC THERAPY; DYSPNEA; ECHOCARDIOGRAPHY; EVIDENCE BASED PRACTICE; EXERCISE TOLERANCE; HEART ATRIUM FIBRILLATION; HEART CATHETERIZATION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART MUSCLE INJURY; HEART MUSCLE NECROSIS; HEART OUTPUT; HEART VENTRICLE PRESSURE; HEART VENTRICLE WALL; HOSPITALIZATION; HUMAN; INOTROPISM; KIDNEY ARTERY STENOSIS; KIDNEY FUNCTION; LIVER FUNCTION; LUNG CONGESTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREVALENCE; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVASCULARIZATION; RISK FACTOR; SLEEP DISORDERED BREATHING; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; TREATMENT RESPONSE; VASOCONSTRICTION; WEIGHT REDUCTION;

ACUTE DISEASE; BIOLOGICAL MARKERS; HEART FAILURE; HUMANS; PROGNOSIS; STROKE VOLUME; VASODILATOR AGENTS;

EID: 84881479017     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-013-0149-5     Document Type: Article

References (59)

1. •• Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. Forecasting the impact of heart failure in the United States: a policy statement from the american heart association. Circ Heart Fail. 2013;6(3):606-19. This analysis underscores the tremendous and growing burden of AHF on the health-care system.
2. Gheorghiade M, Zannad F, Sopko G, Klein L, Piña IL, Konstam MA, et al. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005; 3958-68.
3. Felker GM, Pang PS, Adams KF, Cleland JGF, Cotter G, Dickstein K, et al. Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. Circ Heart Fail. 2010;3(2):314-25.
4. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics - 2013 update a report from the American Heart Association. Circulation. 2012 Dec 12.
5. •• Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251-9. This study documented the increasing prevalence of HFpEF in AHF.
6. Chinali M, Joffe SW, Aurigemma GP, Makam R, Meyer TE, Goldberg RJ. Risk factors and comorbidities in a community-wide sample of patients hospitalized with acute systolic or diastolic heart failure: the Worcester Heart Failure Study. Coron Artery Dis. 2010;21(3):137-43.
7. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355(3):260-9.
8. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with Acute Decompensated Heart Failure with preserved systolic function. J Am Coll Cardiol. 2006;47(1):76-84.
9. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50(8):768-77.
10. Sweitzer NK, Lopatin M, Yancy CW, Mills RM, Stevenson LW. Comparison of clinical features and outcomes of patients hospitalized with Heart Failure and Normal Ejection Fraction (≥55%) Versus those with mildly reduced (40% to 55%) and moderately to severely reduced. Am J Cardiol. 2008;101(8):1151-6.
11. •• Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797-805. This study was one of the few to test the comparative effectiveness of diuretic administration strategies in AHF.
12. Bishu K, Deswal A, Chen HH, LeWinter MM, Lewis GD, Semigran MJ, et al. Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. Am Heart J. 2012;164(5):763-3.
13. Ezekowitz JA, Hu J, Delgado D, Hernandez AF, Kaul P, Leader R, et al. Acute heart failure: perspectives from a randomized trial and a simultaneous registry. Circ Heart Fail. 2012;5(6):735-41.
14. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50(25):2357-68.
15. Munagala VK, Burnett JC, Redfield MM. The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol. 2004;29(12):707-69.
16. Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M, ADHERE Scientific Advisory Committee and Investigators. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol. 2007;49(19):1943-50.
17. Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012;126(1):65-75.
18. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PWF, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109(5):594-600.
19. • Iwanaga Y, Nishi I, Furuichi S, Noguchi T, Sase K, Kihara Y, et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol. 2006;47(4):742-8. This study demonstrated the physiologic basis for lower natriuretic peptides in patients with HFpEF versus HFrEF.
20. Borlaug BA, Redfield MM. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation. 2011;123(18):2006-14.
21. Borlaug BA, Kass DA. Mechanisms of diastolic dysfunction in heart failure. Trends Cardiovasc Med. 2006;16(8):273-9.
22. Lam CSP, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2009;53(13):1119-26.
23. Bursi F, McNallan SM, Redfield MM, Nkomo VT, Lam CSP, Weston SA, et al. Pulmonary pressures and death in heart failure: a community study. J Am Coll Cardiol. 2012;59(3):222-31.
24. Mohammed SF, Roger VL, Abouezzeddine OF, Redfield MM. Right ventricular systolic function in subjects with HFpEF: a community based study. Circulation. 2011 Jun 23;Supplement 1:A17404.
25. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J, et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007;13(6):422-30.
26. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013 Jun 5.
27. Channer KS, McLean KA, Lawson-Matthew P, Richardson M. Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br Heart J. 1994;71(2):146-50.
28. Bart BA, Goldsmith SR, Lee KL, Givertz MM, O'Connor CM, Bull DA, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012;367(24):2296-304.
29. Costanzo MR, Saltzberg MT, Jessup M, Teerlink JR, Sobotka PA, Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure (UNLOAD) Investigators. Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: results from UNLOAD. J Card Fail. 2010;16(4):277-84.
30. Jefferies JL, Bartone C, Menon S, Egnaczyk GF, O'Brien TM, Chung ES. Ultrafiltration in Heart Failure with Preserved Ejection Fraction: comparison with Systolic Heart Failure Patients. Circulation: Heart Failure. 2013 Jun 4.
31. Cotter G, Metra M, Milo-Cotter O, Dittrich HC, Gheorghiade M. Fluid overload in acute heart failure-re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail. 2008;10(2):165-9.
32. • Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA. Effects of vasodilation in heart failure with preserved or reduced ejection fraction. JAC Elsevier Inc. 2012;59(5):442-51. This study demonstrated that unique pathophysiology in HFpEF is associated with differential response to vasodilators.
33. Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz A, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998;351(9100):389-93.
34. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;1787-847.
35. • O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365(1):32-43. This large multinational study demonstrated that vasoactive doses of nesiritide had minimal favorable effects on symptom relief in AHF and were not associated with worsening renal function or increased mortality.
36. Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol. 2013;61(2):196-206.
37. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381(9860):29-39.
38. Bishu K, Hamdani N, Mohammed SF, Krüger M, Ohtani T, Ogut O, et al. Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo. Circulation. 2011;124(25):2882-91.
39. Hamdani N, Bishu KG, Frieling-Salewsky von M, Redfield MM, Linke WA. Deranged Myofilament Phosphorylation and Function in Experimental Heart Failure with Preserved Ejection Fraction. Cardiovascular Research. 2012 Dec 4.
40. Erdmann E, Semigran MJ, Nieminen MS, Gheorghiade M, Agrawal R, Mitrovic V, et al. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Eur Heart J. 2013;34(1):57-67.
41. • Redfield MM. Effect of Phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection FractionA Randomized Clinical Trial Effect of PDE-5 on exercise and clinical Status in HFPEF. JAMA. 2013;309(12):1268. This study examined the effect of sildenafil on exercise capacity and clinical status in ambulatory HFpEF patients. Despite strong rationale for testing this agent in HFpEF, no beneficial effect was seen.
42. van Heerebeek L, Hamdani N, Falcao-Pires I, Leite-Moreira AF, Begieneman MPV, Bronzwaer JGF, et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation. 2012;126(7):830-9.
43. Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006;114(5):397-403.
44. Brandimarte F, Vaduganathan M, Mureddu GF, Cacciatore G, Sabbah HN, Fonarow GC, et al. Prognostic implications of renal dysfunction in patients hospitalized with heart failure: data from the last decade of clinical investigations. Heart Fail Rev. 2013;18(2):167-76.
45. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47(10):1987-96.
46. Giamouzis G, Butler J, Starling RC, Karayannis G, Nastas J, Parisis C, et al. Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) trial. J Card Fail. 2010;16(12):922-30.
47. Riter HG, Redfield MM, Burnett JC, Chen HH. Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. J Am Coll Cardiol. 2006;47(11):2334-5.
48. National Heart Lung and Blood Institute, Blood Institute NHLBI. Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study (ROSE/ REDROSE). ClinicalTrials.gov. Report No.: NCT01132846.
49. Messerli FH, Bangalore S, Makani H, Rimoldi SF, Allemann Y, White CJ, et al. Flash pulmonary oedema and bilateral renal artery stenosis: the Pickering syndrome. Eur Heart J. 2011;32(18):2231-5.
50. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;e463-654.
51. •• Gandhi SK, Powers JC, Nomeir AM, Fowle K, Kitzman DW, Rankin KM, et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med. 2001;344(1):17-22. This is a seminal study that clarified the pathophysiology of HFpEF patients with AHF.
52. Kramer K, Kirkman P, Kitzman D, Little WC. Flash pulmonary edema: association with hypertension and reoccurrence despite coronary revascularization. Am Heart J. 2000;140(3):451-5.
53. Kociol RD, Pang PS, Gheorghiade M, Fonarow GC, O'Connor CM, Felker GM. Troponin elevation in heart failure. JAC Elsevier Inc. 2010;56(14):1071-8.
54. Cotter G, Felker GM, Adams KF, Milo-Cotter O, O'Connor CM. The pathophysiology of acute heart failure - is it all about fluid accumulation? Am Heart J. 2008;155(1):9-18.
55. Borlaug BA, Olson TP, Lam CSP, Flood KS, Lerman A, Johnson BD, et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2010;56(11):845-54.
56. Zakeri R, Borlaug BA, McNulty S, Mohammed SF, Lewis GD, Semigran MJ, et al. Impact of atrial fibrillation on exercise capacity in Diastolic Heart Failure: a RELAX Trial Ancillary Study. J Am Coll Cardiol. 61 10-S.
57. Linssen GCM, Rienstra M, Jaarsma T, Voors AA, Van Gelder IC, Hillege HL, et al. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail. 2011;13(10):1111-20.
58. Bitter T, Faber L, Hering D, Langer C, Horstkotte D, Oldenburg O. Sleep-disordered breathing in heart failure with normal left ventricular ejection fraction. Eur J Heart Fail. 2009;11(6):602-8.
59. Kaneko Y, Floras JS, Usui K, Plante J, Tkacova R, Kubo T, et al. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med. 2003;348(13):1233-41.